SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Costantino who wrote (1097)7/9/1997 1:06:00 PM
From: DZOO   of 1762
 
Rick, about 150,000 people in the US alone suffer from low grade non-Hodgkins lymphoma. Then add to that the worldwide total and you have a substantial potential market. Alas, you are the only one with a product. Nice position to be in, hence IMO billion dollar market. I think Rituxan will be approved also but, the numbers are against us:

1. 70% of phase I drugs complete trials
2. 30% of phase II drugs complete trials
3. 25-30% of phase III drugs complete trials
4. According to FDA, only 20% of drugs that start clinicals are approved.

So, I would say approval is not a done deal nor is it extremely likely.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News